TTC36: A Promising Drug Target and Biomarker for parkinson's disease

Target Name: TTC36

NCBI ID: G143941

TTC36

TTC36: A Promising Drug Target and Biomarker for parkinson's disease

Parkinson's disease is a neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. It affects an estimated 10 million people worldwide and is often associated with reduced quality of life and independence. Despite advances in surgical and therapeutic interventions, the underlying cause of Parkinson's disease remains largely unexplored. However, research has identified several potential drug targets and biomarkers that may provide new insights into the pathophysiology and treatment of this disease. TTC36, a repeat protein 36, is one such promising drug target and biomarker that has received significant attention in recent years.

The Protein 36 Family

Parkinson's disease is caused by the loss of dopamine-producing neurons in the brain. The neurotransmitter dopamine is involved in motor function, and its levels decline in Parkinson's disease is thought to contribute to the motor symptoms. The protein 36 family, which includes TTC36, has been identified as a potential drug target for Parkinson's disease.

TTC36: A Potential Drug Target

TTC36 is a 36-kDa protein that is expressed in various tissues and cells, including brain. It is a member of the superfamily of G-protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play a critical role in cellular signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling.

TTC36 has been shown to interact with several protein partners, including alpha-synuclein, a protein that is aggregated in the brains of people with Parkinson's disease. Alpha-synuclein is a protein that is involved in the formation of beta-sheet aggregates, which are thought to contribute to the neurotoxicity and neurodegeneration associated with Parkinson's disease. TTC36 has also been shown to interact with dopamine receptor subtypes, including D2R, which is involved in motor function.

In addition to its potential role in modulating dopamine signaling, TTC36 has also been shown to play a role in the regulation of ion channels, which are involved in the flow of electrical current through the brain. The disruption of ion channels has been implicated in the neurotoxicity and neurodegeneration associated with Parkinson's disease.

TTC36 as a Biomarker

The assessment of the potential clinical utility of a drug candidate is often based on its potential as a biomarker. TTC36 has been shown to be a potential biomarker for Parkinson's disease in several animal models. In db7 human neuroblastoma cells, overexpression of TTC36 led to an increase in the amount of 伪-synuclein protein that was present, a hallmark of Parkinson's disease. Similarly, in Rhesus Macaque monkeys, administration of a drug that blocked TTC36 signaling led to an improvement in motor function, a finding that is consistent with the hypothesis that TTC36 may be involved in the pathophysiology of Parkinson's disease.

Conclusion

TTC36 is a protein that has been identified as a potential drug target for Parkinson's disease due to its interaction with dopamine-producing neurons and its role in the regulation of ion channels. In addition to its potential as a drug target, TTC36 has also been shown to be a potential biomarker for Parkinson's disease. Further studies are needed to confirm its utility as a drug target and to develop more effective therapies for the treatment of Parkinson's disease.

Protein Name: Tetratricopeptide Repeat Domain 36

The "TTC36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets